Brief Summary
The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy
Protocol Interventions
Drug: Osimertinib, Drug: Pemetrexed, Drug: Carboplatin, Drug: Cisplatin